Benitec Biopharma Inc.
BNTC
$14.61
-$0.33-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -118.60% | -8.22% | 15.03% | -1.27% | 2.68% |
| Total Depreciation and Amortization | 17.78% | 1.25% | 10.98% | 8.33% | -3.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,252.60% | 90.43% | 378.02% | 260.32% | 156.00% |
| Change in Net Operating Assets | 264.21% | -148.13% | -104.40% | 147.75% | -1,185.50% |
| Cash from Operations | 49.97% | -43.58% | -0.20% | 19.58% | -53.09% |
| Capital Expenditure | 96.65% | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 96.65% | -- | -- | 100.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 45,730.77% | -29.88% | -- | -- |
| Repurchase of Common Stock | -23,156.41% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 96,012.82% | -- | -- | -- | -- |
| Cash from Financing | -- | 45,725.64% | -22.44% | -- | -- |
| Foreign Exchange rate Adjustments | -118.26% | 273.62% | -306.67% | -123.81% | 167.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 505.99% | 290.20% | -27.41% | 1,002.40% | -56.35% |